Drug Profile
Latanoprost intratympanic - Synphora
Alternative Names: JB-004Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Synphora
- Class Antiglaucomas; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Meniere's disease; Tinnitus
Highest Development Phases
- Phase II/III Meniere's disease
Most Recent Events
- 04 May 2017 Phase-II/III development for Meniere's disease is ongoing in Sweden (Intratympanic) (Synphora website, May 2017)
- 23 May 2016 Synphora completes a phase II/III trial for Meniere's disease in Sweden (Intratympanic) (EudraCT2013-002261-18; NCT01973114)
- 24 Feb 2016 Latanoprost intratympanic is available for licensing as of 24 Feb 2016. http://www.synphora.com/partnering.html